We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
- Authors
Kherabi, Yousra; Fréchet-Jachym, Mathilde; Rioux, Christophe; Yazdanpanah, Yazdan; Méchaï, Frédéric; Pourcher, Valérie; Robert, Jérôme; Guglielmetti, Lorenzo; MDR-TB Management Group
- Abstract
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
- Subjects
FRANCE; RETROSPECTIVE studies; TREATMENT effectiveness; MYCOBACTERIUM tuberculosis; ANTITUBERCULAR agents; QUINOLONE antibacterial agents
- Publication
Emerging Infectious Diseases, 2022, Vol 28, Issue 9, p1796
- ISSN
1080-6040
- Publication type
journal article
- DOI
10.3201/eid2809.220458